Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Incorporating the American Pharmacists Association's Delivering Medication Therapy Management services certificate program into an accelerated pharmacy curriculum.

Donovan JL, Cross J, Morrill AM, Belliveau PP, Abel CA, Morin AK, Malloy MJ.

Curr Pharm Teach Learn. 2017 Sep;9(5):813-820. doi: 10.1016/j.cptl.2017.05.005. Epub 2017 Jun 11.

PMID:
29233309
2.

Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.

McDaneld PM, Spooner LM, Mohr JF, Belliveau PP.

Ann Pharmacother. 2013 Dec;47(12):1654-65. doi: 10.1177/1060028013508272. Epub 2013 Nov 1. Review.

PMID:
24259618
3.

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Review.

PMID:
21828346
4.

Tigecycline for the treatment of severe Clostridium difficile infection.

Larson KC, Belliveau PP, Spooner LM.

Ann Pharmacother. 2011 Jul;45(7-8):1005-10. doi: 10.1345/aph.1Q080. Epub 2011 Jul 5. Review.

PMID:
21730279
5.

Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.

Gaffney MM, Belliveau PP, Spooner LM.

Ann Pharmacother. 2009 Oct;43(10):1676-83. doi: 10.1345/aph.1M160. Epub 2009 Sep 8. Review.

PMID:
19737995
6.

Elevated creatine phosphokinase levels associated with linezolid therapy.

Allison GW, Perla RJ, Belliveau PP, Angelis SM.

Am J Health Syst Pharm. 2009 Jun 15;66(12):1097-100. doi: 10.2146/ajhp080228.

PMID:
19498124
7.

Emergence of fluoroquinolone only-resistant Escherichia coli in a community hospital.

Perla RJ, Knutson EL, Belliveau PP.

Clin Infect Dis. 2007 May 1;44(9):1255. No abstract available.

PMID:
17407051
8.

Omalizumab: a monoclonal anti-IgE antibody.

Belliveau PP.

MedGenMed. 2005 Jan 27;7(1):27. Review.

9.

Evaluation of omalizumab from a health plan perspective.

Belliveau PP, Lahoz MR.

J Manag Care Pharm. 2005 Nov-Dec;11(9):735-45. Review.

10.

Guidelines for liposomal amphotericin B.

Mazzola JL, Belliveau PP, Cheeseman SH.

Am J Health Syst Pharm. 2003 Jul 15;60(14):1480-1. No abstract available.

PMID:
12892034
11.

Levofloxacin use at an academic teaching institution.

Belliveau PP, Brennan WP, Rothman AL.

Am J Health Syst Pharm. 2000 Oct 1;57(19):1791-3. No abstract available.

PMID:
11030032
12.

Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions.

Lai KK, Kelley AL, Melvin ZS, Belliveau PP, Fontecchio SA.

Infect Control Hosp Epidemiol. 1998 Sep;19(9):647-52.

PMID:
9778162
13.

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.

Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH.

J Antimicrob Chemother. 1997 Jun;39(6):677-86. Review.

PMID:
9222035
14.

Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS.

Klepser ME, Zhu Z, Nicolau DP, Banevicius MA, Belliveau PP, Ross JW, Broisman L, Quintiliani R, Nightingale CH.

Pharmacotherapy. 1996 Jul-Aug;16(4):656-62.

PMID:
8840373
15.

Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium.

Belliveau PP, Rothman AL, Maday CE.

Am J Health Syst Pharm. 1996 Jul 1;53(13):1570-5.

PMID:
8809278
16.

Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias.

Belliveau PP, Freeman CD, Nicolau DP, Nightingale CH, Tessier PR, Quintiliani R.

Am J Health Syst Pharm. 1996 May 1;53(9):1024-7.

PMID:
8744464
17.

Absorption of ciprofloxacin in febrile and afebrile patients.

Patel KB, Belliveau PP, Nightingale CH, Nicolau DP, Quintiliani R.

Int J Antimicrob Agents. 1995 Dec;6(2):119-22.

PMID:
18611695
18.

Implementation of a once-daily aminoglycoside program in a large community-teaching hospital.

Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD.

Hosp Pharm. 1995 Aug;30(8):674-6, 679-80.

PMID:
10144645
19.

Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags.

Belliveau PP, Nightingale CH, Quintiliani R.

Am J Health Syst Pharm. 1995 Jul 15;52(14):1561-3. No abstract available.

PMID:
7552904
20.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R.

Antimicrob Agents Chemother. 1995 Mar;39(3):650-5.

21.

Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid.

Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Banevicius MA, Quintiliani R.

Antimicrob Agents Chemother. 1994 Oct;38(10):2449-51. Erratum in: Antimicrob Agents Chemother 1995 Mar;39(3):795.

22.

Reduction in serum concentrations of ciprofloxacin after administration of ursodiol to a patient with hepatobiliary disease.

Belliveau PP, Nightingale CH, Qunitiliani R, Maderazo EG.

Clin Infect Dis. 1994 Aug;19(2):354-5. No abstract available.

PMID:
7986920
23.

Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens.

Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Quintiliani R.

Am J Hosp Pharm. 1994 Jul 15;51(14):1782-7.

PMID:
7942906
24.

Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection.

Belliveau PP, Nightingale CH, Quintiliani R.

Am J Hosp Pharm. 1994 Apr 1;51(7):901-4.

PMID:
8017440
25.

Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.

Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Tessier PR, Fu Q, Xuan DW, Quintiliani R.

Pharmacotherapy. 1994 Mar-Apr;14(2):185-90.

PMID:
8197037
26.

Lomefloxacin clinical pharmacokinetics.

Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH.

Clin Pharmacokinet. 1993 Jul;25(1):6-19. Review.

PMID:
8394795
27.

Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection.

Belliveau PP, Shea BF, Scavone JM.

Am J Hosp Pharm. 1993 May;50(5):950-2.

PMID:
8506875

Supplemental Content

Loading ...
Support Center